# FDA Inspection 1210052 - Grifols d.b.a. Biomat USA, Inc. - June 29, 2023

Source: https://www.keypedia.com/records/fda_inspections/grifols-dba-biomat-usa-inc/56039748-d1c4-4190-8679-01d8a893af59
Source feed: FDA_Inspections

> FDA Inspection 1210052 for Grifols d.b.a. Biomat USA, Inc. on June 29, 2023. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1210052
- Company Name: Grifols d.b.a. Biomat USA, Inc.
- Inspection Date: 2023-06-29
- Classification: No Action Indicated (NAI)
- Project Area: Blood and Blood Products
- Product Type: Biologics
- Office Name: Center for Biologics Evaluation and Research

## Related Documents

- [FDA Inspection 1020657 - 2017-07-14](https://www.keypedia.com/records/fda_inspections/grifols-dba-biomat-usa-inc/0bffd74c-f3a8-4d37-872c-228da341c836)
- [FDA Inspection 774404 - 2012-03-23](https://www.keypedia.com/records/fda_inspections/grifols-dba-biomat-usa-inc/3c25094b-6e94-4084-9971-64768b292f34)

Company: https://www.keypedia.com/companies/grifols-dba-biomat-usa-inc/41777747-70e5-4c56-8cfb-0e3e9a9d2a50

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d